Rosetta Puts Blood-Based Cancer Screen on Back Burner to Refocus on miRNA Diagnostics (GenomeWeb News)
Filed in Mesothelioma News on Dec.31, 2009
Rosetta Genomics this month announced that it has scaled back its work on a serum-based colon cancer-screening assay based on microRNA biomarkers, less than a year after the company said that commercialization of the test, dubbed miRscreen Colon, had become its top priority.
